In these studies, the range of reported occludin positive cases ranged from 37.3 to 100% in colon cancer [21,22], from 52.8 to 98% in serous ovarian cancer [23,24], and from 8.7 to 70.2% in oral squamous cell carcinoma [25,26]. This evidence concerns the gene OCLN and colonic neoplasm.